AASLD Briefs: Hepatitis C
Executive Summary
Presentations at the American Association for the Study of Liver Diseases conference included anticipated data from Gilead in hepatitis C genotype 3 patients, results from the COSMOS trial pairing Gilead’s sofosbuvir with Janssen’s simeprevir, Phase II data for Merck’s two-drug DAA combo and findings from an HCV collaboration by Boehringer Ingelheim and Presidio.
You may also be interested in...
Deals Of The Week: Exit From Ambit Tie-Up Just A Blip In Astellas’ Oncology Aspirations
DOTW looks at Astellas’ oncology ambitions plus its recent split with partner Ambit, as well as analysis of Shire’s buyout of Premacure, AbbVie’s out-license of an anti-interleukin-13 antibody to Receptos and the Merck/Luminex collaboration on a companion diagnostic for Alzheimer’s disease.
Are Regulators Ready For The Robot Era? ChatGPT Weighs In On EU Regulation
Artificial intelligence model’s comments signal the likely start of computer-generated comments to the US FDA’s public notices.
Pink Sheet Podcast: US FDA Loses Gene Therapy Expert, Humira Biosimilars Launch, FDA Allows In-Person Meetings
Pink Sheet reporters and editors consider the impact of FDA Office of Tissues and Advanced Therapies Director Wilson Bryan’s retirement, the launch of Humira biosimilars and its effect on the biologic market, as well as the FDA moving to hybrid meetings with sponsors.